Dott. Giovanni Salamano Studio Medico

Dott. Giovanni Salamano Studio Medico Da tre generazioni ci occupiamo della salute dei Vercellesi, come Medici di Famiglia dal 1921 ad ogg

 New in the February 26, 2026, issue of NEJM: ⁣⁣Trastuzumab Deruxtecan in HER2-Positive Breast Cancer (phase 3 DESTINY-B...
28/02/2026

New in the February 26, 2026, issue of NEJM: ⁣

Trastuzumab Deruxtecan in HER2-Positive Breast Cancer (phase 3 DESTINY-Breast05 trial) ⁣

Cabotegravir plus Rilpivirine for Persons with HIV (phase 3 LATITUDE trial) ⁣

Rezatapopt in TP53 Y220C–Mutated Tumors (PYNNACLE study) ⁣

Tecovirimat for the Treatment of Mpox (phase 3 STOMP/A5418 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the February 19, 2026, issue of NEJM: ⁣⁣Teclistamab–Daratumumab in Relapsed Multiple Myeloma (phase 3 MajesTEC-3...
28/02/2026

New in the February 19, 2026, issue of NEJM: ⁣

Teclistamab–Daratumumab in Relapsed Multiple Myeloma (phase 3 MajesTEC-3 trial) ⁣

Hematopoietic Stem-Cell Gene Therapy for Cystinosis ⁣

Antibody–Oligonucleotide for Myotonic Dystrophy (MARINA trial) ⁣

Transcatheter Aortic-Valve Replacement at 7 Years (PARTNER 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the February 12, 2026, issue of NEJM: ⁣⁣Interim Analysis of Sibeprenlimab in IgA Nephropathy (phase 3 VISIONARY ...
28/02/2026

New in the February 12, 2026, issue of NEJM: ⁣

Interim Analysis of Sibeprenlimab in IgA Nephropathy (phase 3 VISIONARY trial) ⁣

Atacicept in Patients with IgA Nephropathy (ORIGIN 3 trial) ⁣

Atrial Fibrillation Therapy in Patients with Stents (ADAPT AF-DES trial) ⁣

Adenoviral Inciting Antigen and VITT ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the February 5, 2026, issue of NEJM: ⁣⁣A Placebo-Controlled Trial of Enlicitide (phase 3 CORALreef Lipids trial)...
28/02/2026

New in the February 5, 2026, issue of NEJM: ⁣

A Placebo-Controlled Trial of Enlicitide (phase 3 CORALreef Lipids trial) ⁣

Beta-Blockers after Myocardial Infarction ⁣

Trastuzumab Deruxtecan for HER2-Positive Breast Cancer (phase 3 DESTINY-Breast09 trial)⁣

Enzalutamide in Recurrent Prostate Cancer (phase 3 EMBARK trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the January 29, 2026, issue of NEJM: ⁣⁣Olezarsen for Managing Severe Hypertriglyceridemia (phase 3 CORE-TIMI 72a...
31/01/2026

New in the January 29, 2026, issue of NEJM: ⁣

Olezarsen for Managing Severe Hypertriglyceridemia (phase 3 CORE-TIMI 72a and CORE2-TIMI 72b trials) ⁣

Tenecteplase in Acute Central Retinal Artery Occlusion (phase 3 TenCRAOS trial)⁣

Palbociclib for HR- and HER2-Positive Breast Cancer (phase 3 PATINA trial) ⁣

Etranacogene Dezaparvovec for Hemophilia B (phase 3 HOPE-B study) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among adults in the United Stat...
18/01/2026

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among adults in the United States and other countries. It occurs when deposits called drusen accumulate under the retina and retinal pigment epithelial (RPE) cells (swipe left for Key Concepts) over a lifetime, increasing with age in persons with genetic and environmental risk factors (seen in figure). Patients lose vision when the deposits damage the RPE and photoreceptor cells responsible for vision, either directly (resulting in geographic atrophy) or through the development of new blood vessels beneath the RPE or retina (subretinal neovascularization). An improved understanding of mechanisms that cause subretinal neovascularization led to groundbreaking treatments that interfere with vascular endothelial growth factor (anti-VEGF treatments) and are widely prescribed. However, anti-VEGF treatments do not prevent atrophy, and even with aggressive treatment, many patients with subretinal neovascularization eventually lose vision. Vision loss from geographic atrophy can also occur in the absence of neovascularization when photoreceptors, RPE cells, and the choriocapillaris vessels that supply blood to the outer retina degenerate. Complement inhibitors to slow the progression of geographic atrophy have received regulatory approval in the United States and Australia but not elsewhere, because monthly injections in the vitreous are required and the treatments do not improve vision; rather, they slow disease progression. Vitamin supplements have been shown to reduce the risk of vision loss from both neovascularization and geographic atrophy. However, no treatments have been shown to improve vision after geographic atrophy involves the fovea, located at the center of the macula. ⁣

In NEJM, Holz and colleagues report 12-month results for 32 patients with severe vision loss from AMD complicated by geographic atrophy who received a retinal prosthetic chip to restore vision. The scientific foundations for restoring vision loss in this manner are described in a new editorial by Jacque Duncan, MD. ⁣

Read the full editorial at NEJM.org (link in bio).⁣

 New in the January 15, 2026, issue of NEJM: ⁣⁣Management of Asymptomatic Carotid Stenosis (CREST-2 trials) ⁣⁣Vision Res...
18/01/2026

New in the January 15, 2026, issue of NEJM: ⁣

Management of Asymptomatic Carotid Stenosis (CREST-2 trials) ⁣

Vision Restoration in Geographic Atrophy Due to AMD (PRIMAvera trial): ⁣

Fremanezumab in Children with Episodic Migraine ⁣

CAR T-Cell Therapy for Autoimmune Hemolytic Anemia ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the January 8, 2026, issue of NEJM: ⁣⁣Evolocumab in Patients without Previous MI or Stroke (VESALIUS-CV trial) ⁣...
11/01/2026

New in the January 8, 2026, issue of NEJM: ⁣

Evolocumab in Patients without Previous MI or Stroke (VESALIUS-CV trial) ⁣

Fish Oil, Cardiovascular Events, and Hemodialysis (PISCES trial) ⁣

RSV Prefusion F Vaccine for Older Adults (DAN-RSV phase 4 trial) ⁣

Base-Edited CAR7 T Cells for T-Cell ALL⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the January 1, 2026, issue of NEJM: ⁣⁣Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase...
01/01/2026

New in the January 1, 2026, issue of NEJM: ⁣

Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase 3 trial) ⁣

Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated NSCLC (FLAURA2 phase 3 trial) ⁣

Brain-Penetrant Enzyme Therapy for MPS II ⁣

Talquetamab and Teclistamab for Extramedullary Myeloma (RedirecTT-1 phase 2 study) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the December 18/25, issue of NEJM: ⁣⁣ctDNA-Guided Atezolizumab in Bladder Cancer (IMvigor011 phase 3 trial) ⁣⁣Ca...
01/01/2026

New in the December 18/25, issue of NEJM: ⁣

ctDNA-Guided Atezolizumab in Bladder Cancer (IMvigor011 phase 3 trial) ⁣

Cardiovascular Outcomes with Tirzepatide (SURPASS-CVOT trial) ⁣

Noninferiority of One HPV Vaccine Dose to Two Doses (ESCUDDO trial) ⁣

High-Dose Rifampin in Tuberculous Meningitis (HARVEST phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the December 11, 2025, issue of NEJM: ⁣⁣High-Dose Influenza Vaccine in Older Adults (DANFLU-2 trial) ⁣⁣High-Dose...
01/01/2026

New in the December 11, 2025, issue of NEJM: ⁣

High-Dose Influenza Vaccine in Older Adults (DANFLU-2 trial) ⁣

High-Dose Influenza Vaccine and Hospitalizations (GALFLU trial) ⁣

Ticagrelor and Aspirin after Coronary Surgery (TACSI trial) ⁣

Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the December 4, 2025, issue of NEJM: ⁣⁣Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) ⁣⁣Shunting...
01/01/2026

New in the December 4, 2025, issue of NEJM: ⁣

Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) ⁣

Shunting for Idiopathic Normal-Pressure Hydrocephalus (PENS trial) ⁣

Pegcetacoplan in C3 Glomerulopathy and IC-MPGN (VALIANT phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

Indirizzo

Piazza Solferino N. 3
Vercelli
13100

Orario di apertura

Lunedì 17:00 - 19:00
Martedì 17:00 - 19:00
Mercoledì 10:00 - 12:00
Giovedì 10:00 - 12:00
Venerdì 17:00 - 19:00

Telefono

+393345713761

Sito Web

https://www.miodottore.it/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Dott. Giovanni Salamano Studio Medico pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Dott. Giovanni Salamano Studio Medico:

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

A little help to Health in rural town.

Da tre generazioni lo Studio Medico Salamano si occupa della salute de

i pazienti Vercellesi. Zona posta tra le metropoli di Torino e Milano esattamente a metà strada tra le due città più importanti del Nord Italia è famosa nel mondo agricolo per la presenza della risicoltura resa possibile da Camillo Benso Conte di Cavour, primo ministro del Regno Sabaudo che qui regnava. La presenza del fiume Po e dei suoi maggiori affluenti dalle Alpi che circondano il Piemonte ha reso possibile nei primi dell’800 la costruzione di canali che permettono una abbondante irrigazione di queste terre, prima paludose e bonificate dai Monaci Cistercensi nell’epoca Medioevale intorno al 1200 - 1300 fondando importanti Abazie che facevano capo all’Arcidiocesi di Vercelli. Proprio a causa della posizione immersa nella pianura padana e nel suo clima afoso d’estate e nebbioso d’inverno, questa regione ha una insolitamente elevata percentuale di pazienti sofferenti di osteopatie ( i cosiddetti Reumatismi ) e malattie infettive dell’apparato respiratorio. Recentemente con l’aumento della vita media grazie ai progressi principalmente in capo cardiovascolare si sta assistendo ad un aumento quasi esponenziale dei casi di neoplasie dell’albero respiratorio, dell’apparato gastroenterico e urinario. Il problema dell’inquinamento atmosferico è in questa zona particolarmente evidente per le scarse correnti di aria che possano pulire e rinnovare l’aria ed il puvuscolo atmosferico stagnante in questa regione nonostante sia a carattere rurale e non industriale come le vicine Torino e Milano. Un particolare evidente nel recente passato è la particolare incidenza di Leptospirosi dovuta alla presenza di acqua stagnante nelle risaie dove le contadine lavoravano a piedi scalzi. Tuttavia anche l’artrite reumatoide e le malattie reumatiche in genere hanno una elevata incidenza tanto che fino a pochi anni fa nell’’Ospedale Sant’Andrea di Vercelli era presente un reparto di Reumatologia ( uno dei pochi in Italia e purtroppo recentemente eliminato ). Per tali motivi prima mio nonno Giovanni Dott Salamano ( Nino ) poi mio padre Andre Dott Salamano ed infine il sottoscritto Giovanni Dott Salamano abbiamo dedicato la nostra ”vita“ alla cura ed allo studio delle malattie infettive ( Nonno Nino ), Reumatiche ( papà Andrea ) ed osteometaboliche ( il sottoscritto ), pur mantenendo l’attenzione sulla Medicina Generale che il Medico di Famiglia deve saper affrontare.